New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.

New safety and biomarker results from MK-2214 and MK-1167 advance Merck’s dual approach to Alzheimer therapy.

Two-thirds of participants experienced clinically meaningful response within 3 months; effects sustained through 12 months with mild adverse event profile.

New data reveals evolocumab significantly reduces long-term major cardiovascular event risks in ASCVD patients, enhancing treatment strategies for better outcomes.

Former CBER chief calls claims "misrepresentation." ID experts Offit and Osterholm criticize timing ahead of CDC advisory committee meeting next week.

Clevenger reviews survey findings behind the recent report "The Agitation Blindspot in Alzheimer’s Care."

A regular focus on mental heatlh during follow-ups with patients who have atopic dermatitis can be integrated simply with a few thoughtful questions.

Your daily dose of the clinical news you may have missed.

Mental health apps show high initial uptake but moderate adherence, revealing key factors for improving user retention in clinical trials.

Novo Nordisk submits an FDA application for semaglutide 7.2 mg for chronic weight management, supported by STEP UP trial data showing greater weight loss.

Panelists discuss how elinzanetant offers a safe, effective nonhormonal option for managing VMS in women receiving endocrine therapy for breast cancer.